{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-301187","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.602629+00:00","generated_at":"2026-06-07T09:04:08.748416+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Guardant Health raises $90.7M in registered direct offering with Baillie Gifford","bullets":["Raised ~$90.7M gross via 3,387,446 shares sold at $26.77 each to Baillie Gifford-managed accounts.","Net proceeds ~$90.6M; funds earmarked for general corporate purposes including working capital and capex.","Offering closed Dec 21, 2023; executed under effective shelf registration statement on Form S-3.","CEO Helmy Eltoukhy noted strong support from Baillie Gifford as Guardant expands precision oncology portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-301187","json":"https://secwatch.observer/filing/0001193125-23-301187.json","markdown":"https://secwatch.observer/filing/0001193125-23-301187.md","text":"https://secwatch.observer/filing/0001193125-23-301187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000119312523301187/0001193125-23-301187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000119312523301187/d518375d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:04:08.748416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6aac342ec83e3aa3fec005edd59b44bb192350c","claim":"Guardant Health, Inc. entered into Common Stock Purchase Agreement with certain institutional investors valued at 3,387,446 shares at $26.77 per share, gross proceeds ~$90.7 million (effective 2023-12-20).","evidence_excerpt":"On December 20, 2023, Guardant Health, Inc. (the “Company”) entered into a common stock purchase agreement (the “Purchase Agreement”) for the issuance and sale in a registered direct offering of 3,387,446 shares of the Company’s common stock, par value $0.00001 per share (the “Shares”), to certain institutional investors at an offering price of $26.77 per share, for gross proceeds of approximately $90.7 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000119312523301187/0001193125-23-301187-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"3,387,446 shares at $26.77 per share, gross proceeds ~$90.7 million"},{"label":"Effective","value":"2023-12-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}